Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

Background Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformational outcomes in the treatment of B-cell malignancies, but their widespread use is hindered by technical and logistical challenges associated with ex vivo cell manufacturing. To overcome these challenges, we de...

Full description

Bibliographic Details
Main Authors: Byoung Y Ryu, Kathryn R Michels, Alyssa Sheih, Susana A Hernandez, Alissa H Brandes, Don Parrilla, Blythe Irwin, Anai M Perez, Hung-An Ting, Christopher J Nicolai, Timothy Gervascio, Seungjin Shin, Mark D Pankau, Mason Muhonen, Jessica Freeman, Sarah Gould, Rich Getto, Ryan P Larson, Andrew M Scharenberg, Alessandra M Sullivan, Shon Green
Format: Article
Language:English
Published: BMJ Publishing Group 2023-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/3/e006292.full

Internet

https://jitc.bmj.com/content/11/3/e006292.full

Similar Items